Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/THBS1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/THBS1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/THBS1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/THBS1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/THBS1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004865921 | Oral cavity | NEOLP | smooth muscle cell proliferation | 40/2005 | 184/18723 | 9.53e-06 | 1.82e-04 | 40 |
GO:005090023 | Oral cavity | NEOLP | leukocyte migration | 67/2005 | 369/18723 | 1.04e-05 | 1.96e-04 | 67 |
GO:000862531 | Oral cavity | NEOLP | extrinsic apoptotic signaling pathway via death domain receptors | 23/2005 | 82/18723 | 1.07e-05 | 1.98e-04 | 23 |
GO:001063223 | Oral cavity | NEOLP | regulation of epithelial cell migration | 56/2005 | 292/18723 | 1.07e-05 | 1.98e-04 | 56 |
GO:004866021 | Oral cavity | NEOLP | regulation of smooth muscle cell proliferation | 39/2005 | 180/18723 | 1.33e-05 | 2.37e-04 | 39 |
GO:000716223 | Oral cavity | NEOLP | negative regulation of cell adhesion | 57/2005 | 303/18723 | 1.62e-05 | 2.79e-04 | 57 |
GO:004001314 | Oral cavity | NEOLP | negative regulation of locomotion | 69/2005 | 391/18723 | 2.05e-05 | 3.41e-04 | 69 |
GO:003460532 | Oral cavity | NEOLP | cellular response to heat | 20/2005 | 69/18723 | 2.33e-05 | 3.72e-04 | 20 |
GO:009030323 | Oral cavity | NEOLP | positive regulation of wound healing | 18/2005 | 59/18723 | 2.76e-05 | 4.29e-04 | 18 |
GO:001003833 | Oral cavity | NEOLP | response to metal ion | 66/2005 | 373/18723 | 2.83e-05 | 4.34e-04 | 66 |
GO:007190031 | Oral cavity | NEOLP | regulation of protein serine/threonine kinase activity | 64/2005 | 359/18723 | 2.93e-05 | 4.48e-04 | 64 |
GO:009028711 | Oral cavity | NEOLP | regulation of cellular response to growth factor stimulus | 56/2005 | 304/18723 | 3.55e-05 | 5.20e-04 | 56 |
GO:009009213 | Oral cavity | NEOLP | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 49/2005 | 256/18723 | 3.90e-05 | 5.62e-04 | 49 |
GO:001063424 | Oral cavity | NEOLP | positive regulation of epithelial cell migration | 37/2005 | 176/18723 | 4.37e-05 | 6.14e-04 | 37 |
GO:190303623 | Oral cavity | NEOLP | positive regulation of response to wounding | 20/2005 | 72/18723 | 4.59e-05 | 6.37e-04 | 20 |
GO:007163431 | Oral cavity | NEOLP | regulation of transforming growth factor beta production | 14/2005 | 41/18723 | 5.34e-05 | 7.29e-04 | 14 |
GO:007259332 | Oral cavity | NEOLP | reactive oxygen species metabolic process | 46/2005 | 239/18723 | 5.77e-05 | 7.77e-04 | 46 |
GO:000268331 | Oral cavity | NEOLP | negative regulation of immune system process | 73/2005 | 434/18723 | 6.18e-05 | 8.22e-04 | 73 |
GO:001076121 | Oral cavity | NEOLP | fibroblast migration | 15/2005 | 47/18723 | 7.12e-05 | 9.27e-04 | 15 |
GO:005067323 | Oral cavity | NEOLP | epithelial cell proliferation | 73/2005 | 437/18723 | 7.74e-05 | 9.93e-04 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THBS1 | SNV | Missense_Mutation | | c.3229C>T | p.Arg1077Trp | p.R1077W | P07996 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.2476N>G | p.Met826Val | p.M826V | P07996 | protein_coding | tolerated(0.44) | benign(0.015) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.1472N>A | p.Ile491Asn | p.I491N | P07996 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | rs576321057 | c.2318G>A | p.Arg773His | p.R773H | P07996 | protein_coding | deleterious(0.05) | possibly_damaging(0.591) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD |
THBS1 | SNV | Missense_Mutation | novel | c.905N>T | p.Thr302Ile | p.T302I | P07996 | protein_coding | tolerated(0.05) | benign(0.216) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1869_1870insA | p.Phe624IlefsTer25 | p.F624Ifs*25 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1871_1872insTGTGACCATCAACTCTGTA | p.Thr625ValfsTer30 | p.T625Vfs*30 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.236_237insCTTAA | p.Asp80LeufsTer17 | p.D80Lfs*17 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Nonsense_Mutation | novel | c.237_238insAGTTGAGAGATTTAGCAGCTCAAAAATGTGACCT | p.Asp80SerfsTer2 | p.D80Sfs*2 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.988_989insTTCCAGCCCTGCCATCCGCACTAACTACATTGGCCACAAGACA | p.Glu330ValfsTer19 | p.E330Vfs*19 | P07996 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2&APOS;-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | METHYLCELLULOSE | METHYLCELLULOSE | 9016860 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PROTEIN KINASE C INHIBITOR | | 9223624 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SIMVASTATIN | SIMVASTATIN | 10543307 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | UVB | | 14962109 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ABT-510 | ABT-510 | |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | VESNARINONE | VESNARINONE | 15356428 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ALL-TRANS RETINOIC ACID | | 9447832 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | RETINOIC ACID | | 1430209 |